ReviewJournal of bone metabolism2015
Medication Related Osteonecrosis of the Jaw: 2015 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons.
Review in Journal of bone metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.
- The Use of Human Amniotic Membrane (hAM) as a Treatment Strategy of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review and Meta-Analysis of the Literature.Medicina (Kaunas, Lithuania) · 2023Pooled it
- [Expert consensus on perioperative management of tooth extraction in patients receiving denosumab therapy].Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology · 2026Article
- Calcium Phosphate Bone Substitutes in the Prevention of Bisphosphonate-Related Osteonecrosis of the Jaw: A Review.Journal of functional biomaterials · 2026Review
- Targeted drug repurposing in medication-related osteonecrosis of the jaw: a review of teriparatide and pentoxifylline/α-tocopherol protocols.Frontiers in medicine · 2026Review
- Medication-related osteonecrosis of the jaw: an evidence-based 2025 position statement from a Korean multidisciplinary task force.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2025Review
- Medication-Related Osteonecrosis of the Jaw: An Evidence-Based 2025 Position Statement from a Korean Multidisciplinary Task Force.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Buccodental Toxicities Induced by Tyrosine Kinase Inhibitors in Patients Diagnosed with Renal Cell Carcinoma-A Literature Review.Dentistry journal · 2025Review
- Treatment period and changes in bone markers according to the application of teriparatide in treating medication-related osteonecrosis of the jaw.BMC oral health · 2025Article
- A retrospective study on odontogenic and non-odontogenic medication-related osteonecrosis of the jaw: Potential differences in clinical features and treatment outcomes.Journal of dental sciences · 2025Article
- Chinese expert consensus on the diagnosis and clinical management of medication-related osteonecrosis of the jaw.Journal of bone oncology · 2024Review
- Insights into Medication-Induced Osteonecrosis of the Jaw Through the Application of Salivary Proteomics and Bioinformatics.International journal of molecular sciences · 2024Article
- Pulp and periapical disease as a risk factor for osteonecrosis of the jaw: a national cohort-based study in Korea.Journal of periodontal & implant science · 2024Article
- Asia-Pacific consensus on long-term and sequential therapy for osteoporosis.Osteoporosis and sarcopenia · 2024Review
- Post biphosphonate mandible osteonecrosis: A case study and literature review.Oral oncology reports · 2023Article
- Osteonecrosis of the Jaws: An Update and Review of Literature.Journal of maxillofacial and oral surgery · 2023Review
- Clinical significance of drug cessation on medication-related osteonecrosis of the jaw in patients with osteoporosis.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2023Article
- Medication-Related Osteonecrosis: Why the Jawbone?Dentistry journal · 2023Review
- The effect of drug holiday on preventing medication-related osteonecrosis of the jaw in osteoporotic rat model.Journal of orthopaedic translation · 2023Article
- Management of Tooth Extraction in Patients Taking Antiresorptive Drugs: An Evidence Mapping Review and Meta-Analysis.Journal of clinical medicine · 2022Review
- Identification of Potentially Pathogenic Variants Associated with Recurrence in Medication-Related Osteonecrosis of the Jaw (MRONJ) Patients Using Whole-Exome Sequencing.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bisphosphonates are the most widely prescribed drugs for the treatment of osteoporosis, and are also used in malignant bone metastases, multiple myeloma, and Paget's disease, and provide therapeutic efficacy on those diseases. However, it was reported that occurrence of osteonecrosis of the jaw (ONJ) could be related with bisphosphonate exposures, and there have been many cases regarding this issue. Therefore, a clearer definition and treatment guidelines were needed for this disease. The American Society for Bone and Mineral Research (ASBMR) and American Association of Oral and Maxillofacial Surgeons (AAOMS) reported statements on bisphosphonate-related ONJ (BRONJ), and a revised version was recently presented. In the revised edition, the diagnosis BRONJ was changed to medication-related ONJ (MRONJ), which reflects a consideration of the fact that ONJ also occurs for denosumab, a bone resorption inhibitor of the receptor activator of nuclear factor-kappa B ligand (RANKL) antibody family, and bevacizumab, an anti-angiogenesis inhibitor. In 2009, a statement on ONJ was also reported locally by a relevant organization, which has served as basis for clinical treatment in Korea. In addition to the new official stance of the AAOMS and ASBMR, with an increasing pool of ONJ clinical experience, a revised version of the 2009 local statement is needed. As such, the Korean Society for Bone and Mineral Research (KSBMR) and the Korean Association of Oral and Maxillofacial Surgeons (KAOMS) have collectively formed a committee for the preparation of an official statement on MRONJ, and have reviewed recent local and international data to propose guidelines customized for the local Korean situation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.